A Study to Determine Biopsy Rate in Participants With a First Relapse of Breast Cancer

  • Breast Cancer
Trial Status:


This trial runs in
  • Buenos Aires
  • HPR
  • Rosario
  • San Miguel de Tucumán
Trial Identifier:

NCT02761616 ML30038

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      This is a retrospective, and observational cohort study to determine the proportion of breast cancer first relapses, that are biopsied. The duration of the study will be approximately 24 months.

      Hoffmann-La Roche Sponsor
      NCT02761616 , ML30038 Trial Identifier
      eBC treated participants Treatments
      Breast Cancer Condition

      Eligibility Criteria

      Female Gender
      ≥ 18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Participants with histologically confirmed breast cancer treated for early breast cancer (eBC) with first metastatic relapse disease in the period from January 1, 2014 and December 31, 2015
      Exclusion Criteria

      Not Applicable

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now